

# MC Partners Inc.

Suite 300 – 576 Seymour Street  
Vancouver, BC V6B 3K1  
Tel: (604) 688-6775  
Fax: (604) 688-6995

---

**NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES**

**MC PARTNERS INC. FILES ITS FILING STATEMENT  
IN CONNECTION WITH ITS PROPOSED QUALIFYING TRANSACTION**

**April 26, 2013**

**TSX Venture Exchange  
Trading Symbol: MCT.P**

Vancouver, British Columbia – MC Partners Inc. (“MCP” or the “Company”), a capital pool company listed on the TSX Venture Exchange (the “Exchange”), is pleased to announce that, following the Company’s receipt of the Exchange’s conditional acceptance of the Company’s previously announced proposed qualifying transaction with bioMmune Technologies Inc. (“bioMmune” and the “Proposed Transaction” respectively), the Company has now filed its filing statement in relation to the Proposed Transaction on SEDAR and a copy of same is available under the Company’s profile at [www.sedar.com](http://www.sedar.com).

Completion of the Proposed Transaction is subject to fulfilling all conditions of the Exchange, including but not limited to submission by the sponsor and receipt by the Exchange of a satisfactory sponsor report and completion of a concurrent non-brokered private placement of 10,000,000 units of the Company at a price of \$0.15 per unit for gross proceeds of \$1,500,000 (the “Financing”). Each unit will consist of one common share of the Company and one common share purchase warrant of the Company (the “Warrant”). Each whole Warrant will entitle the holder to purchase one additional common share of the Company at a price of \$0.25 for a period of 12 months from the completion of the Financing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company’s shares are trading at or above a volume weighted average price of \$0.40 for more than 20 trading consecutive days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release.

Upon completion of the Proposed Transaction, the Company will change its name to reflect the nature and character of the business of bioMmune, with the resulting issuer trading as a Tier 2 Research and Development Issuer on the Exchange.

Trading in the shares of the Company will remain halted until such time as the Proposed Transaction is completed.

On behalf of the Board of Directors

*“John Morgan”*

John Morgan  
Chief Executive Officer

For further information please contact:

John Morgan  
Telephone: (604) 614-1385

*Investors are cautioned that, except as disclosed in the filing statement prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.*

*The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.*

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, final Exchange acceptance. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.*

*Investors are cautioned that, except as disclosed in Filing Statement filed in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.*

*The Exchange has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release. Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This press release contains forward-looking information within the meaning of Canadian securities laws. Such information includes, without limitation, information regarding the completion of the Proposed Transaction. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct. Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: Company's ability to complete the Proposed Transaction; the state of the financial markets for the Company's securities; the state of the resulting issuer's industry in the event the Proposed Transaction is completed; recent market volatility; Company's ability to raise the necessary capital or to be fully able to implement its business strategies; and other risks and factors that the Company is unaware of at this time. The reader is referred to the Company's Filing Statement and initial public offering Prospectus for a more complete discussion of applicable risk factors and their potential effects, copies of which may be accessed through the Company's page on SEDAR at [www.sedar.com](http://www.sedar.com).*